Omid Seidizadeh,Andrea Cairo,Ilaria Mancini et al.
Omid Seidizadeh et al.
Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation [0.03%]
患者与失活的脐带血单元之间共有HLA决定簇对双份脐带血移植后复发的影响
Robert Wynn,Fernanda Volt,Philippe Guardiola et al.
Robert Wynn et al.
During double umbilical cord blood transplant (DUCBT), the winning unit (WU) rejects the losing unit (LU) due to WU T-cells directed against the LU mismatched HLA. This immune response might protect against relapse, especially when the pati...
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: Phase 2 ESCALATE trial [0.03%]
艾曲波帕联合免疫抑制治疗儿童重型再生障碍性贫血：ESCALATE二期临床试验
Akiko Shimamura,Alexey Maschan,Caroyln Bennett et al.
Akiko Shimamura et al.
Severe aplastic anemia (SAA) is a rare, life-threatening disease with acquired pancytopenia and hypocellular bone marrow. ESCALATE evaluated eltrombopag in combination with immunosuppressive therapy (IST) in pediatric patients (aged 1 to
Nicholas Chornenki,Lee Mozessohn
Nicholas Chornenki
Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study [0.03%]
Belumosudil减少口腔慢性移植物抗宿主病组织炎症和纤维化：ROCKstar伴生研究
Rubina Sharma,Noa G Holtzman,Iskra Pusic et al.
Rubina Sharma et al.
Belumosudil (KD025), an oral, selective, Rho-associated, coiled-coil containing protein kinase 2 (ROCK2) inhibitor, is approved for third-line treatment of chronic graft-versus-host disease (cGVHD). Previous studies demonstrated that ROCK2 ...
Brentuximab Vedotin and Nivolumab for Untreated Patients with Hodgkin Lymphoma: Long-term Results [0.03%]
关于未经治疗的经典型霍奇金淋巴瘤患者布伦妥昔单抗和纳武利尤单抗长期疗效的分析结果
Bruce David Cheson,Nancy L Bartlett,Betsy Knopf et al.
Bruce David Cheson et al.
Background: Whereas major improvements have been made in advanced Hodgkin lymphoma (HL) outcomes of patients > 60 yrs are suboptimal with greater toxicity compared with younger patients. In the first phase II study of BV-...
Kirsten M Williams,Vibha N Lama,Kenneth R Cooke et al.
Kirsten M Williams et al.
Use of the Microfluidic Impedance Red Cell Assay (MIRCA) in Sickle Cell Disease [0.03%]
用于镰状细胞病的微流控阻抗红细胞检测(MIRCA)的方法及其应用
Akshay Amit Patwardhan,Ashwin P Patel,Abhinav K Pasupuleti et al.
Akshay Amit Patwardhan et al.
In sickle cell disease (SCD), red blood cells (RBC) are poorly deformable, even under normoxia. With deoxygenation, deformability of sickle RBCs is further reduced due to polymerization of hemoglobin S (HbS). Rigid, poorly deformable sickle...
Targeting Siglec-Sialic Acid Checkpoint to Reverse Immune Dysfunction Mediated by Plasmacytoid Dendritic Cells in Myeloma [0.03%]
靶向Siglec-唾液酸检查点逆转浆细胞样树突状细胞介导的多发性骨髓瘤免疫功能障碍
Arghya Ray,Leutz Buon,Xueping Wan et al.
Arghya Ray et al.
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomas [0.03%]
TRANS-CAR研究：CD19 CAR-T治疗套细胞淋巴瘤转化后复发难治患者的真实世界疗效分析
Pierre Stephan,Roberta Di Blasi,Louise Roulin et al.
Pierre Stephan et al.
Anti-CD19 chimeric antigen receptor (CAR) T cells have shown impressive results in the treatment of relapsed/refractory aggressive large B-cell lymphomas (LBCLs). However, the prognostic value of the LBCL histological subtype in the context...